Jupiter Wellness announced the launch of a clinical trial to evaluate the efficacy of an improved formulation of NoStingz jellyfish sting prevention sunscreen against man-o-war jellyfish. The trial, conducted by Angelshark Consulting and led by Dr. Patric Rice and Dr. Eric Stroud, will take place in the Florida Keys. The launch of this trial marks a milestone for Jupiter Wellness, as the company continues to explore new technology and innovations in the sun care industry. The trial will evaluate the human response to stings from man-o-war jellyfish when protective sunscreen developed by Jupiter is applied. Jupiter Wellness has an exclusive license to the jellyfish sting prevention technology from Shark Defense Technologies, LLC, Oak Ridge, NJ.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JUPW:
- Jupiter Wellness appoints Hector Alila to board of directors
- Jupiter Wellness says reedemable digital coupons available for all shareholders
- Jupiter Wellness announces $4.1M registered direct and private placement
- Jupiter Wellness CEO says positioned for ‘profitable’ 2023
- Jupiter Wellness commences trading on Upstream